Company Description
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins.
It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers.
The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies.
Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
| Country | United States |
| IPO Date | Jun 24, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 133 |
| CEO | Dr. Markus Warmuth M.D. |
Contact Details
Address: 645 Summer Street Boston, Massachusetts United States | |
| Website | https://www.monterosatx.com |
Stock Details
| Ticker Symbol | GLUE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001826457 |
| CUSIP Number | 61225M102 |
| ISIN Number | US61225M1027 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Markus Warmuth M.D. | President, Chief Executive Officer & Director |
| Jennifer Champoux | Chief Operating Officer |
| Andrew Funderburk | Senior Vice President and Head of IR & Strategic Finance |
| Dr. Filip Janku M.D., Ph.D. | Chief Medical Officer |
| Dr. John C. Castle Ph.D. | Chief Data & Information Officer |
| Dr. Sharon Townson Ph.D. | Chief Scientific Officer |
| Edmund Dunn | Vice President & Corporate Controller |
| Magnus Walter DPHIL | Senior Vice President of Drug Discovery |
| Philip Nickson J.D., Ph.D. | Chief Business & Legal Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 10, 2025 | 8-K | Current Report |
| Jan 06, 2025 | 4 | Filing |
| Jan 06, 2025 | 4 | Filing |
| Jan 06, 2025 | 4 | Filing |
| Jan 06, 2025 | 4 | Filing |
| Jan 06, 2025 | 4 | Filing |
| Jan 06, 2025 | 4 | Filing |
| Dec 13, 2024 | 4 | Filing |
| Dec 13, 2024 | 3 | Filing |
| Dec 13, 2024 | 8-K | Current Report |